Abstract
In the article by Sambrook et al.,1 articaine is wrongly blamed to be a risk factor for methaemoglobinaemia in humans. In the article by Wilburn-Goo and Lloyd,2 cited as reference 18 by Sambrook et al., articaine is not even mentioned at all. Higher doses of articaine than commonly administered in dental practice did not increase methaemoglobin in humans undergoing liposuction.3, 4 Besides, prilocaine which is without any doubt the local anaesthetic with the highest potency to induce methaemoglobinaemia, the second amide local anaesthetic mentioned by Wilburn-Goo and Lloyd2 is lidocaine. This is in line with conclusions from an extensive review of local anaesthetics that metabolize to 2,6-xylidine (bupivacaine, etidocaine, lidocaine, mepivacaine and ropivacaine) or o-toluidine (prilocaine).5 These two metabolites of amide local anaesthetics have a carcinogenic potential. Whereas 2,6-xylidine is classified by the International Agency for Research on Cancer as possibly carcinogenic (group 2B), o-toluidine is classified as carcinogenic to humans (group 1).6 Recently, oral administration of prilocaine has been shown to result in high adduct levels of o-toluidine, a direct proof of its metabolic activation to a carcinogen.7 This should be another reason to avoid therapeutic use of prilocaine when ever possible.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.